Ferriscan receives FDA approval

By Melissa Trudinger
Friday, 28 January, 2005

Inner Vision Biometrics (IVB), a subsidiary of Perth based Resonance Health (ASX: RHT) has received FDA marketing approval for its novel diagnostic test for liver iron concentrations.

The FerriScan test non-invasively measures the iron content of the liver, and can be used to detect and treat iron overload disorders including thalassemia and hereditary haemochromatosis using specifically configured MRI machines. Scan data is analysed at a centralised IVB image processing centre using proprietary software.

FerriScan has already been approved for listing by the TGA and has received CE Mark approval in Europe, where partnerships with diagnostic imaging companies are already in place.

"We will be meeting with major US-based diagnostic imaging groups over the next several weeks to accelerate arrangements for the US commercial launch of the FerriScan test," said Resonance's executive director Tony Fitzgerald.

Related News

'Low-risk' antibiotic linked to rise of dangerous superbug

A new study has challenged the long-held belief that rifaximin — commonly prescribed to...

Robotic hand helps cultivate baby corals for reef restoration

The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...

Stem cell experiments conducted in space

Scientists are one step closer to manufacturing stem cells in space — which could speed up...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd